Cargando…
Avoiding rash decisions about zoster vaccination: insights from cost-effectiveness evidence
de Boer and colleagues present a cost-effectiveness analysis based in the Netherlands of two vaccines available for the prevention of herpes zoster. Zostavax® was the first vaccine available for the prevention of herpes zoster in older adults. A live-attenuated vaccine, Zostavax is not free of limit...
Autores principales: | Good, Chester B., Parekh, Natasha, Hernandez, Inmaculada |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6298010/ https://www.ncbi.nlm.nih.gov/pubmed/30558674 http://dx.doi.org/10.1186/s12916-018-1231-3 |
Ejemplares similares
-
Vaccination against herpes zoster in developed countries: State of the evidence
por: Drolet, Mélanie, et al.
Publicado: (2013) -
Segmental Zoster Abdominal Paresis without Skin Rash
por: Hashimoto, Tadayuki, et al.
Publicado: (2020) -
Skin rashes after SARS‐CoV‐2 vaccine: which relationship, if any?
por: Patruno, Cataldo, et al.
Publicado: (2021) -
A case of cutaneous metastasis mimicking herpes zoster rash
por: Chiang, Angela, et al.
Publicado: (2018) -
Varicella Zoster Virus Meningitis with Absence of Rash in an Immunocompetent Child
por: Lagrine, Mariam, et al.
Publicado: (2021)